Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 82,971 shares at $1.07 ($89K) on 2025-12-11, disclosed to the SEC on 2025-12-12.
Scheduled sale ($89k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.06 | 37,104 | $39K | 44.4% |
| 2 | $1.07 | 28,009 | $30K | 33.8% |
| 3 | $1.08 | 17,858 | $19K | 21.8% |
| Total | $1.07 avg | 82,971 | $89K | 100% |
| Filing → |
| HOWL | SELL | 2026-06-10 | $28K | — | Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |